SynthesisFrontiers in oncology2025
Atopic dermatitis and lymphoma risk: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk for second primary malignancies in patients with multiple myeloma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Cutaneous T-cell lymphoma and dupilumab for atopic dermatitis: Practical guidance for a clinical conundrum.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Safety of Dupilumab and Risk of Cutaneous T-Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data-Driven Guide to Counseling Patients and Families.Pediatric dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between atopic dermatitis (AD) and lymphoma risk remains debate. This study systematically evaluates lymphoma risk in AD patients compared to non-AD individuals. Methods: A systematic search of PubMed, Embase, and the Cochrane Library (up to August 11, 2024) identified observational studies reporting lymphoma risk estimates for AD patients. Pooled odds ratios (OR) or relative risks (RR) with 95% CIs were calculated using a random-effects model (PROSPERO ID: CRD42024577019). Results: Of 2,366 articles were screened, 13 studies met the inclusion criteria. AD was significantly associated with elevated lymphoma risk (OR = 2.56, 95% CI: 1.75-3.74, P < 0.001; RR = 1.23, 95% CI: 1.15-1.31, P < 0.001). The risk increased with AD severity, with severe cases showing the highest effect size (RR = 2.63; 95% CI: 1.94-3.58, P < 0.001; OR = 2.60; 95% CI: 1.71-3.96, P < 0.001). Subgroup analyses revealed high risks for Hodgkin lymphoma (HL) (RR = 1.54, 95% CI: 1.35-1.75, P < 0.001) and non-Hodgkin lymphoma (RR = 1.15, 95% CI: 1.04-1.28, P = 0.006). Notably, T-cell lymphoma (TCL) showed the highest risk (OR = 4.25; 95% CI: 1.94-9.33, P < 0.001). whereas no significant association was observed for B-cell lymphoma (OR = 1.07; 95% CI: 0.95-1.20, P = 0.271). Conclusion: AD is significantly association with increased lymphoma risk, particularly HL, NHL and TCL. AD severity may amplify this risk. Future research is warranted to explore underlying mechanisms and address limitations in the current evidence. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024577019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.